Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.
 
 

PPC IV Literature Review Requirements (self-directed learning assignment): Oncology Topics

Breast cancer

  • Comparing trastuzumab to bevacizumab for the treatment of breast cancer
  • Zoledronate versus ibandronate for the treatment of breast cancer
  • Anastrozole versus tamoxifen for the treatment of breast cancer
  • Letrozole versus tamoxifen for treating breast cancer
  • Letrozole versus anastrozole for treating breast cancer
  • Comparing trastuzumab monotherapy to T-DM1 for second-line treatment of HER-2 positive breast cancer
  • PF005280014 (trastuzumab biosimilar) versus trastuzumab for breast cancers involving HER2+ expression
  • Feasibility and Safety of Arm vs. Chest Ports in Patients with Breast Cancer
  • Comparing ultrasonography and mammography to mammography alone for breast cancer screening

Cervical/Endometrial Cancers

  • Laparotomy or laparoscopy in the treatment of high-risk endometrial cancer patients
  • Comparing laparoscopy to laparotomy as surgical treatment for cervical cancer
  • HPV screening versus pap test for cervical cancer screening
  • Laparoscopy versus laparotomy in treating endometrial cancer

Lung cancer

  • Comparing gefitinib versus docetaxel in treating non-small-cell lung cancer
  • Comparing vorinostat/paclitaxel to paclitaxel alone for treating non-small-cell lung cancer
  • Comparing vorinostat/carboplatin to carboplatin alone for treating non-small-cell lung cancer
  • Comparing atezolizumab to docetaxel for patients for treating non-small-cell lung cancer
  • Comparing nivolumab to docetaxel for treating non-small-cell lung cancer

  • Comparing atezolizumab and docetaxel for treatment of non-small cell lung cancer

  • Collateral Sensitivity in ALK-rearranged Non-small Cell Lung Cancer

  • Paclitaxel/carboplatin and Paclitaxel/cisplatin: Advanced Non-Small Cell Lung Cancer Treatment

Melanoma

  • Ipilimumab and sargramostim compared to ipilimumab for treating metastatic melanoma
  • Nivolumab vs ipilimumab for treating melanoma
  • Nivolumab vs Ipilimumab vs  Nivolumab and Ipilimumab for treating advanced melanoma
  • Vemurafenib vs dabrafenib vs trametinib for treating metastatic melanoma

Misc. oncology topics

  • Denosumab versus zoledronic acid for treating bone metastases in advanced cancer
  • Comparing adjuvant sunitinib to sorafenib for treating non-metastatic renal-cell carcinoma
  • Temozolomide vs. Standard PCV for treating high-grade gliomas
  • Comparing the pain intensity and misconceptions among hospice patients with cancer and their caregivers
  • Eicosapentaenoic acid versus aspirin for the prevention of colorectal adenomas
  • Nilotinib versus imatinib for treating Philadelphia chromosome positive chronic myeloid leukemia
  • Comparing radical prostatectomy to watchful waiting for treating early prostate cancer
  • Computed virtual chromoendoscopy vs. conventional colonoscopy
  • Chimeric antigen receptor-modified T cells to treat leukemia. Special topic: see H. McEwen for help with article selection

Accelerated approval for new cancer drugs

  • Vemurafenib (formerly PLX4032) for treating metastatic melanoma. Find one randomized control trial comparing this drug to another drug. For your second article, find an article testing PLX4032 on cancer cell lines. Choose a review article of your choice.
  • Crizotinib for treating non-small cell lung cancer. See H. McEwen about the choosing your articles.